Integration of Pharmaceutical Discovery and Development

Case Histories

AvRonald T. Borchardt,Roger M. Freidinger

Häftad, Engelska, 2010

Del i serien Pharmaceutical Biotechnology

2 134 kr

Beställningsvara. Skickas inom 10-15 vardagar. Fri frakt över 249 kr.

Beskrivning

This volume provides case histories illustrating the types of interdisciplinary interactions necessary to design drug candidates with optimal pharmacological, pharmaceutical, biopharmaceutical, and metabolic/pharmacokinetic properties. Key features include an incisive discussion of HIV protease inhibitors and 287 illustrations.

Produktinformation

Utgivningsdatum:2010-12-07
Mått:152 x 229 x 35 mm
Vikt:924 g
Format:Häftad
Språk:Engelska
Serie:Pharmaceutical Biotechnology
Antal sidor:610
Förlag:Springer-Verlag New York Inc.
ISBN:9781441932884

Utforska kategorier

Innehållsförteckning

Renin Inhibitors.- The Discovery and Development of Angiotensin II Antagonists.- Development of an Orally Active Tripeptide Arginal Thrombin Inhibitor.- Discovery and Development of an Endothelin a Receptor-Selective Antagonist PD 156707.- Endothelin Receptor Antagonists.- LHRH Antagonists.- LHRH Agonists.- Discovery and Development of Somatostatin Agonists.- Factors Impacting the Delivery of Therapeutic Levels of Pyrone-Based HIV Protease Inhibitors.- The Integration of Medicinal Chemistry, Drug Metabolism, and Pharmaceutical Research and Development in Drug Discovery and Development.- De Novo Design and Discovery of Cyclic HIV Protease Inhibitors Capable of Displacing the Active-Site Structural Water Molecule.- Discovery and Development of the BHAP Nonnucleoside Reverse Transcriptase Inhibitor Delavirdine Mesylate.- Famciclovir.- The Use of Esters as Prodrugs for Oral Delivery of ?-Lactam Antibiotics.- Hematoregulators.- Discovery and Development of GG745, a Potent Inhibitor of Both Isozymes of of 5?-Reductase.- Discovery of a Potent and Selective ?1A Antagonist.- Discovery of Bioavailable Inhibitors of Secretory Phospholipase A2.- The Anxieties of Drug Discovery and Development.- CI-1015.- Orally Active Nonpeptide CCK-A Agonists.- Orally Active Growth Hormone Secretagogues.- Dorzolamide, a 40-Year Wait.- Discovery and Development of Novel Melanogenic Drugs.